Skip Navigation

European Journal of Heart Failure 2000 2(2):167-173; doi:10.1016/S1388-9842(00)00073-8
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tio, R. A.
Right arrow Articles by Mulder, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tio, R. A.
Right arrow Articles by Mulder, N. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2000 European Society of Cardiology

Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction

René A. Tioa,*, Judith Niekenb,c, Elisabeth G.E. de Vriesb, Carolein Pfeiffera, Mike J.L. de Jongstea, Els Piepera, Han Moshaged, Piet C. Limburgc and Nanno H. Mulderb

a Thoraxcenter, Department of Cardiology, University Hospital Groningen P.O. Box 30.001, 9700 Groningen, The Netherlands
b Department of Internal Medicine, Division of Medical Oncology, University Hospital Groningen P.O. Box 30.001, 9700 Groningen, The Netherlands
c Department of Internal Medicine, Division of Clinical Immunology, University Hospital Groningen P.O. Box 30.001, 9700 Groningen, The Netherlands
d Department of Internal Medicine, Division of Gastroenterology and Hepatology, University Hospital Groningen P.O. Box 30.001, 9700 Groningen, The Netherlands

* Corresponding author. Tel.: +31-50-3612365; fax: +31-50-3614643. E-mail address: r.a.tio{at}thorax.azg.nl (R.A. Tio).


  Abstract

Experimental data have shown that rIL2 has negative inotropic properties. This has not been investigated in humans with normal left ventricular function. Seventeen consecutive renal cell carcinoma patients who received rIL2 therapy because of dissemination were analyzed before and after treatment with a low dose of rIL2 subcutaneously. Left ventricular ejection fraction (echocardiography), heart rate variability parameters (24 h electrocardiography), and TNF{alpha}, IL1β and nitric oxide metabolites (NOx) were measured. LVEF decreased from 54 ± 7 to 50 ± 6% (mean ± S.D.; P = 0.012), with a concomitant increase in heart rate from 87 ± 13 to 94 ± 13 beats/min (P = 0.031). All frequency domain HRV parameters decreased: the total power from 18.0 ± 7.9 to 14.0 ± 5.0 ms (P = 0.001), the low frequency from 10.3 ± 5.4 to 8.3 ± 3.4 ms (P = 0.001), and the high frequency from 6.3 ± 2.6 to 4.5 ± 1.1 ms (P = 0.001). There was no measurable effect on TNF{alpha}, IL1β concentrations. Plasma levels of nitrate (NOx) increased from 22.8 ± 14.4 to 41.8±26.6 µmol/l (P = 0.007).

Conclusions: A low dose of rIL2 has a negative inotropic effect that may be mediated by increased NO concentrations. It also reduces sympathetic activity as reflected in HRV parameters.

Key Words: Heart failure • Interleukin-2 • Nitric oxide • Heart rate variability

Received September 23, 1999; Revised February 23, 2000; Accepted March 6, 2000


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.